Editas Medicine (EDIT) announced the appointment of Linda Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas’ drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications. Prior to joining Editas, Dr. Burkly held positions of increasing responsibility over a 37-year tenure at Biogen (BIIB), most recently leading neuroscience-focused research teams as Vice President and Senior Distinguished Investigator from 2014 to 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
- Largest borrow rate increases among liquid names
- Editas Medicine 12.5M share Spot Secondary priced at $10.00
- Editas Medicine Announces Pricing of Offering of Common Stock
- Planned Stock Offering Puts EDIT Stock in a Tailspin